electroCore Aims Noninvasive Neurostimulation At The Masses

Armed with a $40 million Series A financing, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. With drug firms upping their interest in so-called “electroceuticals,” it could signal a shift away from certain pharmaceutical treatments.

Vagus nerve stimulation (VNS) has been around for decades in implanted devices. But a few companies, with New Jersey's electroCore LLC at the forefront, are developing noninvasive VNS devices (nVNS). electroCore's lead product delivers a mild electrical signal to the cervical branch of the vagus nerve.

With no surgery needed, the technology’s proponents say it could eventually supplant pharmaceutical solutions. “I think it’s something that can compete at the front end of the continuum of care,”...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography